TAK-931 – A CDC7 Inhibitor in Solid Tumors | Dosage Collision Study Shows Treatment is Tolerable

admin

6 years ago

Ana Limon Carrera, Takeda Oncology, shares TAK-931 – A CDC7 Inhibitor in Solid Tumors | Dosage Collision Study Shows Treatment is Tolerable at Annual Meeting 2018